<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Treatments with monoclonal antibodies targeting the epidermal growth factor receptors (EGFR) have improved the prognosis of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Mutated KRAS status is predictive of resistance to anti-EGFR agents and allows the selection of KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> patients who may benefit from these targeted therapies </plain></SENT>
<SENT sid="2" pm="."><plain>We report an original case of metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> including three synchronous <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> with three different KRAS statuses </plain></SENT>
<SENT sid="3" pm="."><plain>We discuss the possible therapeutic impact of this clinical case and the role of multiple samplings for KRAS status determination </plain></SENT>
</text></document>